Italia markets open in 5 hours 59 minutes

Qiagen N.V. (QGEN)

NYSE - Nasdaq Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
47,85+0,65 (+1,38%)
Alla chiusura: 04:00PM EDT
47,85 0,00 (0,00%)
Dopo ore: 04:33PM EDT

Qiagen N.V.

Hulsterweg 82
Venlo 5912 PL
Netherlands
31 77 355 6600
https://www.qiagen.com

Settore/iHealthcare
SettoreDiagnostics & Research
Impiegati a tempo pieno6.000

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Thierry BernardCEO, MD & Member of Management Board2,02MN/D1965
Dr. Roland SackersCFO, MD & Member of Management Board1,18MN/D1969
Mr. Antonio SantosSr. VP & Head of Global OperationsN/DN/DN/D
Mr. John GilardiVP of Corp. Communications & Investor RelationsN/DN/DN/D
Ms. Stephany FosterSr. VP & Head of HRN/DN/DN/D
Dr. Thomas SchweinsSr. VP of Life Science Bus. AreaN/DN/DN/D
Dr. Thomas TheuringerSr. Director & Head of External CommunicationsN/DN/DN/D
Mr. Jean-Pascal ViolaSr. VP & Head of Molecular Diagnostics Bus. AreaN/DN/DN/D
Dr. Jonathan G. Sheldon Ph.D.Sr. VP of Qiagen Digital Insights Bus. AreaN/DN/D1972
Mr. Thomas NeidertVP of Global TreasuryN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Governance aziendale

L'ISS Governance QualityScore di Qiagen N.V. al 1 luglio 2022 è 5. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 3; diritti degli azionisti: 9; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.